» Articles » PMID: 27002521

The Relevance of 'mixed Anxiety and Depression' As a Diagnostic Category in Clinical Practice

Overview
Specialties Neurology
Psychiatry
Date 2016 Mar 23
PMID 27002521
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

According to ICD-10 criteria, mixed anxiety and depressive disorder (MADD) is characterized by co-occurring, subsyndromal symptoms of anxiety and depression, severe enough to justify a psychiatric diagnosis, but neither of which are clearly predominant. MADD appears to be very common, particularly in primary care, although prevalence estimates vary, often depending on the diagnostic criteria applied. It has been associated with similarly pronounced distress, impairment of daily living skills, and reduced health-related quality of life as fully syndromal depression and anxiety. Although about half of the patients affected remit within a year, non-remitting patients are at a high risk of transition to a fully syndromal psychiatric disorder. The validity and clinical usefulness of MADD as a diagnostic category are under debate. It has not been included in the recently released DSM-5 since the proposed diagnostic criteria turned out to be not sufficiently reliable. Moreover, reviewers have disputed the justification of MADD based on divergent results regarding its prevalence and course, diagnostic stability over time, and nosological inconsistencies between subthreshold and threshold presentations of anxiety and depressive disorders. We review the evidence in favor and against MADD and argue that it should be included into classification systems as a diagnostic category because it may enable patients to gain access to appropriate treatment early. This may help to reduce patients' distress, prevent exacerbation to a more serious psychiatric disorder, and ultimately reduce the societal costs of this very common condition.

Citing Articles

Prevalence, Symptom Profiles, and Correlates of Mixed Anxiety-Depression in Male and Female Autistic Youth.

Bitsika V, Sharpley C, Vessey K, Evans I NeuroSci. 2024; 5(3):315-327.

PMID: 39483279 PMC: 11477927. DOI: 10.3390/neurosci5030025.


Physical Distancing and Mental Well-Being in Youth Population of Portugal and Brazil during the COVID-19 Pandemic.

Gil J, Vargues Aguiar P, Azeredo-Lopes S, Soares P, Moura H, Arcencio R Port J Public Health. 2024; 40(2):91-100.

PMID: 39469085 PMC: 11320111. DOI: 10.1159/000525248.


Multidimensional Study of the Attitude towards Euthanasia of Older Adults with Mixed Anxiety-Depressive Disorder.

Fonseca L, Castro L, Rego G, Nunes R Healthcare (Basel). 2024; 12(11).

PMID: 38891153 PMC: 11171529. DOI: 10.3390/healthcare12111078.


The brain-bone axis: unraveling the complex interplay between the central nervous system and skeletal metabolism.

Shi H, Chen M Eur J Med Res. 2024; 29(1):317.

PMID: 38849920 PMC: 11161955. DOI: 10.1186/s40001-024-01918-0.


Concentrated transdiagnostic and cross-disciplinary micro-choice based group treatment for patients with depression and with anxiety leads to lasting improvements after 12 months: a pilot study.

Wilhelmsen-Langeland A, Bortveit T, Jurgensen M, Softeland E, Hystad S, Kvale G BMC Psychiatry. 2024; 24(1):361.

PMID: 38745158 PMC: 11094865. DOI: 10.1186/s12888-024-05786-0.


References
1.
Bauer M, Pfennig A, Severus E, Whybrow P, Angst J, Moller H . World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013; 14(5):334-85. DOI: 10.3109/15622975.2013.804195. View

2.
Wittchen H, Essau C . Comorbidity and mixed anxiety-depressive disorders: is there epidemiologic evidence?. J Clin Psychiatry. 1993; 54 Suppl:9-15. View

3.
Stahl S . Mixed depression and anxiety: serotonin1A receptors as a common pharmacologic link. J Clin Psychiatry. 1997; 58 Suppl 8:20-6. View

4.
Hranov L . Comorbid anxiety and depression: illumination of a controversy. Int J Psychiatry Clin Pract. 2014; 11(3):171-89. DOI: 10.1080/13651500601127180. View

5.
Zilles K, Palomero-Gallagher N, Grefkes C, Scheperjans F, Boy C, Amunts K . Architectonics of the human cerebral cortex and transmitter receptor fingerprints: reconciling functional neuroanatomy and neurochemistry. Eur Neuropsychopharmacol. 2002; 12(6):587-99. DOI: 10.1016/s0924-977x(02)00108-6. View